ABSTRACT
Delafloxacin (ABT-492, RX-3341, WQ-3034) is a novel fluoroquinolone developed initially by Wakunaga Pharmaceutical Co. (Osaka & Hiroshima, Japan), licensed initially in 1999 to Abbott Park (IL), then in 2006 to Rib-X Pharmaceuticals (now Melinta Therapeutics, New Haven, CT), where it has been developed under the brand name Baxdela. It has a molecular weight of 440.76 g/mol and is an anionic fluoroquinolone with the chemical formula 1-(6-amino3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxy-azetidin-l-yl)-4-oxo-l,4-dihydroquinoline-3-carboxylic acid. Its empirical formula is C18H12ClF3N4O4. The chemical structure is shown in Figure 108.1. Chemical structure of delafloxacin. https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781315152110/08d8042d-9481-4a8d-8c27-9bd589f6de6b/content/fig108_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
